Lifevantage Corporation (LFVN) Peer Comparison
$6.17
$0.07
(1.06%)
As on 04-Sep-2026 13:16EDT
Market cap
$80 Mln
Revenue (TTM)
$183 Mln
P/E Ratio
15.9
P/B Ratio
2.4
Div. Yield
0 %
Edit
| Lifevantage Corporation (LFVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
80 | 14,975 | 12,310 | 11,972 | 10,425 |
Revenue ($ Mln) |
183 | 692 | 831 | 5,020 | 777 |
Net Profit ($ Mln) |
5.07 | -696.24 | 54.90 | -199.00 | -191.64 |
Net Margin (%) |
2.78 | -100.64 | 6.61 | -3.96 | -24.68 |
RoE (%) |
14.87 | -- | 8.11 | -3.03 | -223.36 |
Price to Earnings |
15.89 | -- | 264.84 | -- | -- |
Price-To-Book |
2.41 | 123.68 | 17.91 | 1.79 | 129.60 |
Income Statement ($ Mln)
| Lifevantage Corporation (LFVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
182.59 | -- | -- | -- | -- |
|
Cost of Revenue
|
40.97 | -- | -- | -- | -- |
|
Gross Profit
|
141.61 | -- | -- | -- | -- |
|
Operating Expenses
|
135.91 | -- | -- | -- | -- |
|
Operating Profit (EBIT)
|
5.70 | -- | -- | -- | -- |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
6.07 | -- | -- | -- | -- |
|
Provision for Tax
|
0.99 | -- | -- | -- | -- |
|
Profit after Tax (Net Income)
|
5.07 | -- | -- | -- | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Lifevantage Corporation (LFVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
33.59 | -- | -- | -- | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
8.30 | -- | -- | -- | -- |
|
Current Liabilities
|
20.23 | -- | -- | -- | -- |
|
Total Liabilities
|
62.11 | -- | -- | -- | -- |
Assets ($ Mln)
| Lifevantage Corporation (LFVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
23.81 | -- | -- | -- | -- |
|
Current Assets
|
38.30 | -- | -- | -- | -- |
|
Total Assets
|
62.11 | -- | -- | -- | -- |
|
Total Debt*
|
9.87 | -- | -- | -- | -- |
|
Net Current Assets
|
-- | -- | -- | -- | -- |
Cashflow ($ Mln)
| Lifevantage Corporation (LFVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
10.24 | -- | -- | -- | -- |
|
Cash Flow from Investing Activities
|
-7.31 | -- | -- | -- | -- |
|
Cash from Financing Activities
|
-7.78 | -- | -- | -- | -- |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Lifevantage Corporation (LFVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
11.30 | -- | -- | -- | -- |
|
ROE (%)
|
14.87 | -- | -- | -- | -- |
|
ROA (%)
|
7.57 | -- | -- | -- | -- |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
2.78 | -- | -- | -- | -- |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Lifevantage Corporation (LFVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.20 | -- | -- | -- | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-48.27 | -- | -- | -- | -- |
|
EPS Growth (%)
|
-0.47 | -- | -- | -- | -- |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Lifevantage Corporation (LFVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
15.63 | -- | -- | -- | -- |
|
Price / Book Value
|
2.36 | -- | -- | -- | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
8.76 | -- | -- | -- | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Lifevantage Corporation (LFVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.29 | -- | -- | -- | -- |
|
Short term debt to equity ratio
|
0.06 | -- | -- | -- | -- |
|
Current Ratio
|
1.89 | -- | -- | -- | -- |
|
Quick Ratio
|
1.09 | -- | -- | -- | -- |
|
Interest Coverage
|
-- | -- | -- | -- | -- |
Operating Efficiency Ratios
| Lifevantage Corporation (LFVN) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
1.64 | -- | -- | -- | -- |
|
Asset Turnover
|
2.72 | -- | -- | -- | -- |
|
Receivable days
|
6.92 | -- | -- | -- | -- |
|
Inventory Days
|
164.19 | -- | -- | -- | -- |
|
Payable days
|
45.53 | -- | -- | -- | -- |
|
Cash Conversion Cycle
|
125.58 | -- | -- | -- | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
